Biohit Oyj to share study protocols

Biohit Oyj November 12, 2013 at 2 P.M. local time (EET)

Finnish healthcare company Biohit Oyj has made a decision to share study protocols, i.e., descriptions of clinical studies designed for validation of Biohit Oyj’s diagnostic tests as well as for evaluation of therapeutic efficacy of Biohit’s Acetium capsule and lozenge products in current and novel clinical indications.

CEO Semi Korpela, Biohit Oyj: “While making all research protocols publicly available through Biohit company website, Biohit Oyj has the intention to stimulate interest in these diagnostic tests and therapeutic products all over the world.”

http://www.biohithealthcare.com/scientific/study-protocols

Additional information:

 CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”. The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve people’s quality of life by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit’s series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com